

Development of personalized solid cancer therapy with neoantigen targeted TCR-T cells



ONCOLOGY	Candidate
Product Type	Personalized T cell product
Indication	Solid cancer
Target	Patient-specific Neoantigen(NeoAg)
MoA(Mechanism of Action)	Recognize MHC-NeoAg complex → T cell activation → Secretion of cytotoxic cytokine, IFN- γ , granzyme, perforin, etc. → Tumor cell killing
Competitiveness	First-in-class Identification of neoantigen presented by actual binding to HLA through immunopeptidome analysis. Retention of TIL banking as T cell source for the screening of neoantigen targeted TCRs Application of various TCR using transposon system
Development Stage	Candidate
Route of Administration	Parenteral-intravenous